Recent Company News

• 06:48 AM ET Apr 13, 2026
  

  Eli Lilly reports Phase 3 BRUIN CLL-322 trial of Jaypirca combination in r/r CLL/SLL met primary endpoint ($939.47, 0.00)

• 11:13 PM ET Mar 08, 2026
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 09:18 PM ET Mar 17, 2026
  

  Nippon Shinyaku launches ELZONRIS injection for treatment of blastic plasmacytoid dendritic cell neoplasm in Japan (¥5188.0000, -54)

• 09:28 AM ET Mar 10, 2026
  

  Capricor Therapeutics announces new PDUFA date for Deramiocel BLA as 22-Aug-26

• 08:47 AM ET Mar 06, 2026
  

  Roche's Genentech announces detailed analysis of the Phase III ALLEGORY trial of Gazyva (obinutuzumab) in adults with systemic lupus erythematosus (SLE) was published in the New England Journal of Medicine (NEJM) (CHF 342.60, -8.90)

• 06:43 AM ET Feb 27, 2026
  

  NMPA approves Innovent Biologics's Jaypirca for new indication to treat CLL/SLL (HK$85.10, 0.00)

• 07:07 PM ET Feb 23, 2026
  

  Nippon Shinyaku grants marketing authorization from UCB for Fintepla oral solution in Japan effective 1-Apr-26 (¥5015.0000, 0)

• 08:46 PM ET Feb 11, 2026
  

  NICE recommends Genentech's Gazyvaro with mycophenolate mofetil to treat lupus nephritis (CHF 356.80, 0.00)

• 08:44 AM ET Feb 10, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market